Stockscreener 앱 받기
1.22
2.47%
0.02
전일 마감가:
$1.20
열려 있는:
$1.24
하루 거래량:
2.78M
Relative Volume:
0.26
시가총액:
$328.64M
수익:
$188.87M
순이익/손실:
$-400.38M
주가수익비율:
-0.8133
EPS:
-1.5
순현금흐름:
$-260.90M
1주 성능:
-7.55%
1개월 성능:
-33.54%
6개월 성능:
-32.07%
1년 성능:
-68.55%
1일 변동 폭
$1.20
$1.2595
1주일 범위
$1.18
$1.47
52주 변동 폭
$1.16
$4.10
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.225 | 328.64M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
126.18 | 221.85B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
97.13 | 142.24B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
370.29 | 140.07B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
93.11 | 118.98B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.74 | 40.31B | 5.72B | 4.17B | 259.90M | 6.97 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-04-18 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
Pacific Biosciences secures extended lease with rent abatement - Investing.com
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Re - GuruFocus.com
2024 SMRT Conserve grant winners - Pacific Biosciences
Pacific Biosciences of California, Inc. to Host Earnings Call - ACCESS Newswire
Selected publications from February 2025 - Pacific Biosciences
Pacific Biosciences COO Mark Van Oene sells $9,125 in company stock - Investing.com Canada
Pacific Biosciences CEO sells $17,583 in stock By Investing.com - Investing.com South Africa
Pacific Biosciences CEO sells $17,583 in stock - Investing.com
ARK Investment Management LLC Buys 2,637,961 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Rare Disease Month: Putting People First - Pacific Biosciences
Pacific Biosciences of California (PACB) Stock Moves -1.18%: What You Should Know - MSN
Investor Network: Pacific Biosciences of California, Inc. to Host Earnings Call - ACCESS Newswire
Chromosome-level genome assembly and improved annotation of onion genome ( Allium cepa L.) - Nature.com
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock - Seeking Alpha
Pacific Biosciences of California's (PACB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells $45,776.12 in Stock - MarketBeat
PacBio cut to Neutral at Goldman Sachs after guidance cut - MSN
Revenue Downgrade: Here's What Analysts Forecast For Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14% - Yahoo Finance
Analysts Issue Forecasts for PACB FY2025 Earnings - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
A chromosome-scale reference assembly of Vigna radiata enables delineation of centromeres and telomeres - Nature.com
How HiFi sequencing is making a difference for rare disease research at Children’s Mercy - Pacific Biosciences
Traders Purchase High Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB) - MarketBeat
Pacific Biosciences Executives Conduct Major Stock Transactions - TradingView
Pacific Biosciences Officer Sells Over 259K Shares - TradingView
PacBio to Present at TD Cowen's 45th Annual Health Care Conference on March 4, 2025 - Nasdaq
The Goldman Sachs Group Cuts Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.50 - MarketBeat
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference - Quantisnow
Life sciences stocks fall on NIH funding concerns - MSN
Where Pacific Biosciences Stands With Analysts - Benzinga
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by StockNews.com - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownTime to Sell? - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Announces Quarterly Earnings Results - MarketBeat
StockWatch: NIH Indirect Cost Cuts Shake Tools Stocks - Genetic Engineering & Biotechnology News
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN
Sumitomo Mitsui Trust Group Inc. Decreases Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Stephens Reiterates Overweight Rating for Pacific Biosciences of California (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript - Insider Monkey
Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday - MarketBeat
PacBio's Strategic Talent Move: 700K Share Package Signals Major Executive Addition - StockTitan
PacBio Grants Equity Incentive Award to New Employee - Quantisnow
PacBio Grants Equity Incentive Award to New Employee - GlobeNewswire Inc.
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Ca - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Releases Earnings Results, Meets Estimates - MarketBeat
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - Benzinga
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall - Yahoo Finance
UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating - Marketscreener.com
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
퍼시픽 바이오 사이언스 주식 (PACB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
6,486 |
9,126 |
1,497,695 |
| Farmer Michele | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
2,973 |
4,183 |
184,619 |
0.57%
0.83%
자본화:
|
볼륨(24시간):